Aimee Wilkin to Antiretroviral Therapy, Highly Active
This is a "connection" page, showing publications Aimee Wilkin has written about Antiretroviral Therapy, Highly Active.
Connection Strength
0.459
-
O'Connor J, Vjecha MJ, Phillips AN, Angus B, Cooper D, Grinsztejn B, Lopardo G, Das S, Wood R, Wilkin A, Klinker H, Kantipong P, Klingman KL, Jilich D, Herieka E, Denning E, Abubakar I, Gordin F, Lundgren JD. Effect of immediate initiation of antiretroviral therapy on risk of severe bacterial infections in HIV-positive people with CD4 cell counts of more than 500 cells per µL: secondary outcome results from a randomised controlled trial. Lancet HIV. 2017 03; 4(3):e105-e112.
Score: 0.142
-
Vissman AT, Young AM, Wilkin AM, Rhodes SD. Correlates of HAART adherence among immigrant Latinos in the Southeastern United States. AIDS Care. 2013; 25(3):356-63.
Score: 0.105
-
Vissman AT, Hergenrather KC, Rojas G, Langdon SE, Wilkin AM, Rhodes SD. Applying the theory of planned behavior to explore HAART adherence among HIV-positive immigrant Latinos: elicitation interview results. Patient Educ Couns. 2011 Dec; 85(3):454-60.
Score: 0.094
-
Townsend D, Troya J, Maida I, Pérez-Saleme L, Satta G, Wilkin A, Barreiro P, Pegram PS, Soriano V, Mura MS, Núñez M. First HAART in HIV-infected patients with high viral load: value of HIV RNA levels at 12 weeks to predict virologic outcome. J Int Assoc Physicians AIDS Care (Chic). 2009 Sep-Oct; 8(5):314-7.
Score: 0.086
-
Floris-Moore MA, Mollan K, Wilkin AM, Johnson MA, Kashuba AD, Wohl DA, Patterson KB, Francis O, Kronk C, Eron JJ. Antiretroviral activity and safety of once-daily etravirine in treatment-naive HIV-infected adults: 48-week results. Antivir Ther. 2016; 21(1):55-64.
Score: 0.032